The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

Westmead Hospital, Sydney

Eastern Health (Box Hill Hospital), Box Hill

The University of Queensland - Princess Alexandra Hospital (PAH), Woolloongabba

Memorial Sloan-Kettering Cancer Center, New York

Alexandra General Hospital of Athens, Athens

Charite-Universitatsmedizin, Berlin

Hospital of the University of Pennsylvania, Philadelphia

Universitatsklinikum Hamburg-Eppendorf (UKE, Hamburg

Policlinica San Matteo, Pavia

Duke University Medical Center, Durham

Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda

Mayo Clinic, Jacksonville

Vanderbilt University Medical Center, Nashville

The Cleveland Clinic, Cleveland

Universitätsklinikum Essen, Essen

Indiana University Simon Cancer Center, Indianapolis

Karmanos Cancer Institute, Detroit

Froedtert & Medical College of Wisconsin, Cancer Center - Froedtert Hospital, Milwaukee

Mayo Clinic - Minnesota, Rochester

University of Chicago Medicine, Chicago

Universitatsklinikum Heidelberg, Heidelberg

Hopitaux Lyon Sud, Pierre-Bénite

Hôpital Pitié-Salpêtrière, Paris

University of Texas; MD Anderson Cancer Center, Houston

Colorado Blood Cancer Institute, Denver

Hôpital Dupuytren - CHU Limoges, Limoges

City of Hope, Duarte

Hadassah University Medical Center, Jerusalem

Stanford Cancer Institute (SCI), Stanford

Oregon Health & Science University, Portland

University of Washington/Seattle Cancer Care Alliance, Seattle

Tufts Medical Center, Boston

Boston University School of Medicine, Boston

Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien, Vienna

CHU Rennes, Service de Medecine Interne, Rennes

University Hospital of Patras, Pátrai

Southampton General Hospital, Southampton

Hospital Clinic de Barcelona, Barcelona

Centre for Clinical Haematology, Birmingham

The Royal Free London NHS Foundation Trust - The Royal Free Hospital, London